- Deficit spending: Trump was bad, but Biden has been worse.
- Cause of inflation: Trump bears some blame, but again, Biden has been worse.
- “The Biden administration wants to throw a grenade into this carefully balanced ecosystem for research, development, and commercialization of a new medical technology.”
- We may be able to use CRISPR to treat rare inflammatory diseases.
Category: Health Economics & Costs
Should Outcomes Research Discount Quality of Life when Computing Value?
To gauge the relative value of any health intervention the outcome needs to be measured and compared to some desired result. Cost effectiveness analysis is a tool used to compare the cost of outcomes from various interventions. For instance, preventive medical services are compared to other lifesaving interventions using the outcome life years saved. This allows public health advocates to decide how to allocate scare resources.
Friday Links
- “You can very clearly halve your children’s risk of schizophrenia through polygenic selection, which costs only a few hundred dollars if you’re already doing IVF…. In a decade or two you can probably eliminate the risk entirely.”
- Roughly 90 percent of Americans are effectively blocked from opening an HSA.
- How to create HSAs in the Obamacare Exchanges. (National Review)
- Americans who trust the government to do the right thing most of the time: 10% Elites: 79% Super Elites: 89%. Maybe that’s because the elites run the government.
- What the future holds for weight loss drugs. (Bloomberg)
- Have economists oversold the idea of “moral hazard”?
Thursday Links
- Prescription drug pricing: Most cost-effectiveness analyses exclude probable end-of-patent, life cycle pricing – and set the initial price too low.
- Private approaches may be the best answer to public health problems.
- Rep Michael Burgess on why the CBO needs to consider the long-term benefits of preventive medicine.
- Looks like there are more deaths by fire than by ice. But there are still more deaths by cold than by warming.